Osteoarthritis (OA) affects the entire knee joint, yet cross-tissue molecular interplay remains poorly understood. To address this, we constructed the first single-cell RNA sequencing atlas of knee OA, profiling articular cartilage, meniscus, synovium, and subchondral bone. Our analysis revealed that healthy synovium and meniscus harbor abundant tissue stem cells (TSCs) and immune cells, which are significantly altered in OA. Regenerative TSCs expressing SDF1, SOX9, CD146, PDGFRB, and CD105 are reduced, while osteogenic TSCs marked by NT5E are expanded. OA cartilage has distinct MMP13-producing detrimental chondrocytes while increasing RUNX2-producing chondrocytes and fibroblasts. OA tissues are enriched with inflammatory (IL1B-IL6-NOS2-TNF) and pain-marker (P2RX7)-specific macrophages, inflammatory genes expression and immune cells. Cell-cell communication contributes to OA progression, promotes proinflammatory macrophages, and osteogenic TSCs. By identifying these OA-specific cells and molecular interplay, and constructing the first multi-tissue comprehensive atlas, we bridge the critical knowledge gaps and lay the foundation for advancing targeted OA therapies.
12 January 2021 in Communication in Biomathematical Sciences
Dengue is one of the major health problems in Bangladesh and many people are died in recent years due to the severity of this disease. Therefore, in this paper, a SIRS model for the human and SI model for vector population with saturated incidence rate and constant treatment function has been presented to describe the transmission of dengue. The equilibrium points and the basic reproduction number have been computed. The conditions which lead the disease free equilibrium and the endemic equilibrium have been determined. The local stability for the equilibrium points has been established based on the eigenvalues of the Jacobian matrix and the global stability has been analyzed by using the Lyapunov function theory. It is found that the stability of equilibrium points can be controlled by the reproduction number. In order to calculate the infection rate, data for infected human populations have been collected from several health institutions of Bangladesh. Numerical simulations of various compartments have been generated using MATLAB to investigate the influence of the key parameters for the transmission of the disease and to support the analytical results. The effect of treatment function over the infected compartment has been illustrated. The sensitivity of the reproduction number concerning the parameters of the model has been analyzed. Finally, the most sensitive parameter that has the highest effect over reproduction number has been identified.
17 April 2025 in International Journal of Oral Science
Oral squamous cell carcinoma (OSCC) progresses from preneoplastic precursors via genetic and epigenetic alterations. Previous studies have focused on the treatment of terminally developed OSCC. However, the role of epigenetic regulators as therapeutic targets during the transition from preneoplastic precursors to OSCC has not been well studied. Our study identified lysine-specific demethylase 1 (LSD1) as a crucial promoter of OSCC, demonstrating that its knockout or pharmacological inhibition in mice reversed OSCC preneoplasia. LSD1 inhibition by SP2509 disrupted cell cycle, reduced immunosuppression, and enhanced CD4+ and CD8+ T-cell infiltration. In a feline model of spontaneous OSCC, a clinical LSD1 inhibitor (Seclidemstat or SP2577) was found to be safe and effectively inhibit the STAT3 network. Mechanistic studies revealed that LSD1 drives OSCC progression through STAT3 signaling, which is regulated by phosphorylation of the cell cycle mediator CDK7 and immunosuppressive CTLA4. Notably, LSD1 inhibition reduced the phosphorylation of CDK7 at Tyr170 and eIF4B at Ser422, offering insights into a novel mechanism by which LSD1 regulates the preneoplastic-to-OSCC transition. This study provides a deeper understanding of OSCC progression and highlights LSD1 as a potential therapeutic target for controlling OSCC progression from preneoplastic lesions.
Poor infiltration of CD8+ T cells and dysregulation of MHC class I (MHC-I) confer resistance to anticancer immunotherapies. Inhibition of the epigenetic regulator lysine-specific demethylase 1 (LSD1) has been shown to increase CD8+ T-cell infiltration in head and neck squamous cell carcinoma (HNSCC). In this study, we aimed to elucidate the mechanisms of LSD1 inhibition in antitumor immunity in HNSCC to aid in the development of effective therapeutic strategies. LSD1 inhibition in syngeneic and chronic tobacco carcinogen–induced HNSCC mouse models increased the recruitment of activated dendritic cells (DC), as well as CD4+ and CD8+ T cells, and the expression of IFNγ in CD8+ T cells, CXCL9 in DCs, and CXCR3 in CD4+ T cells. Humanized HNSCC mice and patient data validated the inverse correlation of KDM1A with DC markers, CD8+ T cells, and their activating chemokines. Kdm1a knockout in mouse HNSCC and LSD1 inhibitor treatment of human HNSCC cells cocultured with human peripheral blood mononuclear cells resulted in MHC-I upregulation in cancer cells. LSD1 inhibition promoted CD8+ T-cell activation via a DC-dependent mechanism and induced efficient antigen presentation in CD8+ T cells. Finally, LSD1 inhibition increased H3K4me2 at the promoters of DC-related markers (BATF3 and CXCL9), T-cell markers (CXCR3), and MHC-I (HLA-A). Overall, LSD1 inhibition in tumor cells upregulates MHC-I expression and stimulates CXCL9 secretion by DCs to enhance antigen presentation and promote CD8+ T-cell activation via the CXCL9–CXCR3 signaling axis, resulting in increased IFNγ production. This may have implications for treating poorly immunogenic and immunotherapy-resistant cancers. Significance: LSD1 inhibition enhances antigen presentation and reprograms the tumor microenvironment by inducing infiltration of T cells and dendritic cells, activating antitumor immunity and providing an epigenetic therapy for head and neck cancer.
4 February 2026 in International Journal of Oral Science
Temporomandibular joint osteoarthritis (TMJ-OA) affects a significant proportion of the population worldwide. However, there has been no substantial progress in the development of FDA-approved drugs for treatment due to a lack of understanding of the specific factors regulating key TMJ-OA molecular mechanisms. Lysyl Oxidase-Like-2 (LOXL2) promotes knee joint cartilage protection and is downregulated in a TMJ-OA animal model. We evaluated the role of LOXL2 in TMJ cartilage, its molecular mechanism, and gene networks using in vivo Loxl2 knockout mice ( Acan-Cre; Loxl2flox/flox ) and ex vivo goat TMJ cartilage. Our results show that Loxl2 knockout in mouse cartilage upregulates Il1b , Mmp9 , Mmp13 , Adamts4 , and Adamts5 , but reduces the levels of aggrecan and proteoglycan. Loxl2 deleted TMJ cartilage show a higher enrichment of inflammatory response, TNFA signaling via NF-κB, extracellular matrix (ECM), and collagen degradation pathway network. Conversely, LOXL2 treatment reduces interleukin-1 beta (IL-1β)-induced expression of Mmp13 , protects mitochondrial function, and ECM from degeneration. Importantly, LOXL2 attenuates IL-1β-induced chondrocyte apoptosis via the phosphorylation of NF-κB and expression of the pain-related gene PTGS2 (encodes COX2). Taken together, Loxl2 knockout mice exacerbate TMJ-OA through cartilage/ECM degradation, mitochondrial dysfunction, chondrocyte apoptosis, and inflammatory gene expression, whereas LOXL2 treatment mitigate these effects.